Abstract
Introduction
: Adipokines have an important role in development and progression of type 2 diabetes mellitus (T2DM) and its complications such as nephropathy. Asprosin is a recently discovered adipokine that involve in glucose metabolism and inflammation process. The present study sought to evaluate asprosin levels in patients with T2DM and T2DM + nephropathy (NP) compared to controls and its relation with markers of insulin resistance, inflammation and renal function.
Methods
Serum levels of asprosin, adiponectin, IL-6 and TNF-α were measured in 55 control, 54 T2DM and 55 T2DM + NP patients using ELISA kits.
Results
Asprosin was found to be higher in T2DM (6.73 ± 1.67) and T2DM + NP (7.11 ± 1.54) compared to controls (4.81 ± 1.09) (p < 0.001), while adiponectin indicated a lower concentration in both patient groups compared with controls. Moreover, IL-6 and TNF-α indicated higher levels in both patients group compared with controls. Asprosin indicated a positive correlation with HbA1c, FBG, TC, LDL-C, IL-6 and TNF-α in T2DM group. In the patients with T2DM + NP asprosin positively correlated with BMI, HbA1c, insulin, HOMA-IR, Cr, UAE, IL-6 and TNF-α and inversely correlated with eGFR.
Conclusion
Higher concentration of asprosin in T2DM and T2DM + NP and its relation with glucose and lipid metabolism, and markers of renal function and inflammation suggested a possible role for this adipokine in the pathogenesis of T2DM and nephropathy.